Phase II study with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel with metronomic cyclophosphamide as a preoperative treatment of triple-negative breast cancer

Research output: Contribution to journalArticle

Abstract

Background The aggressive biological behavior and the lack of target therapy prompts the search for new therapeutic approaches for triple-negative breast cancers. Patients and Methods We evaluated the efficacy in terms of Ki-67 variation and clinical response but also the toxicity of a neoadjuvant regimen based on metronomic principles including ECF (epidoxorubicin with cisplatin on day 1 with low-dose 5-fluorouracil in continuous infusion every 21 days for 4 courses) followed by paclitaxel (90 mg/m2) on day 1, 8, and 15 every 28 days for 3 courses in combination with metronomic oral cyclophosphamide 50 mg/d for 12 weeks in patients with HER2-negative breast cancer (T2-T4a-d, N0-3, M0) with estrogen receptor and progesterone receptor <10%. Results We enrolled 34 patients from June 2009 to May 2013. All were considered evaluable on an intention-to treat basis. The mean difference between the percentage of Ki-67 positive cells evaluated in surgical resection specimens and in pretreatment tumor core biopsy was 41% (95% confidence interval [CI], 30-51; P

Original languageEnglish
Pages (from-to)259-265
Number of pages7
JournalClinical Breast Cancer
Volume15
Issue number4
DOIs
Publication statusPublished - 2015

Fingerprint

Triple Negative Breast Neoplasms
Epirubicin
Paclitaxel
Fluorouracil
Cyclophosphamide
Cisplatin
Progesterone Receptors
Estrogen Receptors
Therapeutics
Confidence Intervals
Breast Neoplasms
Biopsy
Neoplasms

Keywords

  • Chemotherapy
  • Ki-67
  • Metronomic therapy
  • Neoadjuvant
  • Pathological complete response

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{e25c7610174c4ed68f27f10114a81e81,
title = "Phase II study with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel with metronomic cyclophosphamide as a preoperative treatment of triple-negative breast cancer",
abstract = "Background The aggressive biological behavior and the lack of target therapy prompts the search for new therapeutic approaches for triple-negative breast cancers. Patients and Methods We evaluated the efficacy in terms of Ki-67 variation and clinical response but also the toxicity of a neoadjuvant regimen based on metronomic principles including ECF (epidoxorubicin with cisplatin on day 1 with low-dose 5-fluorouracil in continuous infusion every 21 days for 4 courses) followed by paclitaxel (90 mg/m2) on day 1, 8, and 15 every 28 days for 3 courses in combination with metronomic oral cyclophosphamide 50 mg/d for 12 weeks in patients with HER2-negative breast cancer (T2-T4a-d, N0-3, M0) with estrogen receptor and progesterone receptor <10{\%}. Results We enrolled 34 patients from June 2009 to May 2013. All were considered evaluable on an intention-to treat basis. The mean difference between the percentage of Ki-67 positive cells evaluated in surgical resection specimens and in pretreatment tumor core biopsy was 41{\%} (95{\%} confidence interval [CI], 30-51; P",
keywords = "Chemotherapy, Ki-67, Metronomic therapy, Neoadjuvant, Pathological complete response",
author = "Giuseppe Cancello and Vincenzo Bagnardi and Claudia Sangalli and Emilia Montagna and Silvia Dellapasqua and Andrea Sporchia and Monica Iorfida and Giuseppe Viale and Massimo Barberis and Paolo Veronesi and Alberto Luini and Mattia Intra and Aron Goldhirsch and Marco Colleoni",
year = "2015",
doi = "10.1016/j.clbc.2015.03.002",
language = "English",
volume = "15",
pages = "259--265",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Phase II study with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel with metronomic cyclophosphamide as a preoperative treatment of triple-negative breast cancer

AU - Cancello, Giuseppe

AU - Bagnardi, Vincenzo

AU - Sangalli, Claudia

AU - Montagna, Emilia

AU - Dellapasqua, Silvia

AU - Sporchia, Andrea

AU - Iorfida, Monica

AU - Viale, Giuseppe

AU - Barberis, Massimo

AU - Veronesi, Paolo

AU - Luini, Alberto

AU - Intra, Mattia

AU - Goldhirsch, Aron

AU - Colleoni, Marco

PY - 2015

Y1 - 2015

N2 - Background The aggressive biological behavior and the lack of target therapy prompts the search for new therapeutic approaches for triple-negative breast cancers. Patients and Methods We evaluated the efficacy in terms of Ki-67 variation and clinical response but also the toxicity of a neoadjuvant regimen based on metronomic principles including ECF (epidoxorubicin with cisplatin on day 1 with low-dose 5-fluorouracil in continuous infusion every 21 days for 4 courses) followed by paclitaxel (90 mg/m2) on day 1, 8, and 15 every 28 days for 3 courses in combination with metronomic oral cyclophosphamide 50 mg/d for 12 weeks in patients with HER2-negative breast cancer (T2-T4a-d, N0-3, M0) with estrogen receptor and progesterone receptor <10%. Results We enrolled 34 patients from June 2009 to May 2013. All were considered evaluable on an intention-to treat basis. The mean difference between the percentage of Ki-67 positive cells evaluated in surgical resection specimens and in pretreatment tumor core biopsy was 41% (95% confidence interval [CI], 30-51; P

AB - Background The aggressive biological behavior and the lack of target therapy prompts the search for new therapeutic approaches for triple-negative breast cancers. Patients and Methods We evaluated the efficacy in terms of Ki-67 variation and clinical response but also the toxicity of a neoadjuvant regimen based on metronomic principles including ECF (epidoxorubicin with cisplatin on day 1 with low-dose 5-fluorouracil in continuous infusion every 21 days for 4 courses) followed by paclitaxel (90 mg/m2) on day 1, 8, and 15 every 28 days for 3 courses in combination with metronomic oral cyclophosphamide 50 mg/d for 12 weeks in patients with HER2-negative breast cancer (T2-T4a-d, N0-3, M0) with estrogen receptor and progesterone receptor <10%. Results We enrolled 34 patients from June 2009 to May 2013. All were considered evaluable on an intention-to treat basis. The mean difference between the percentage of Ki-67 positive cells evaluated in surgical resection specimens and in pretreatment tumor core biopsy was 41% (95% confidence interval [CI], 30-51; P

KW - Chemotherapy

KW - Ki-67

KW - Metronomic therapy

KW - Neoadjuvant

KW - Pathological complete response

UR - http://www.scopus.com/inward/record.url?scp=84946488526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946488526&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2015.03.002

DO - 10.1016/j.clbc.2015.03.002

M3 - Article

C2 - 25933934

AN - SCOPUS:84946488526

VL - 15

SP - 259

EP - 265

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 4

ER -